Every material Form 8-K Erasca, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Erasca, Inc. said its Chief Operating Officer, Nicholas (Nik) Chetwyn, Ph.D., will leave the company, with employment ending November 2, 2026. The company said duties overseen by the COO are moving to other leadership team members to streamline its reporting structure. The filing does not disclose a successor or any financial terms of the departure.
Chief Operating Officer Nicholas (Nik) Chetwyn, Ph.D., employment terminates effective November 2, 2026
Decision made October 15, 2026, as part of a leadership realignment
COO responsibilities are transitioning to other members of the leadership team
Filing does not name a replacement or disclose separation terms
Erasca announced that the FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. The designation can allow more frequent FDA interactions and may expedite review, but it does not change approval standards or increase the likelihood of U.S. marketing approval.
FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma, announced August 24, 2026.
Designated programs may gain more frequent FDA interactions and may be eligible for accelerated approval, priority review, or rolling review if criteria are met.
The FDA may later revoke the designation or decide review timing will not be shortened.
The company plans a phase 3 trial in pancreatic cancer and two potentially registration-enabling lung cancer trials.
Erasca reported a second-quarter 2026 net loss of $44.1 million, or $(0.14) per share, up from $33.9 million, or $(0.12) per share, a year earlier, as research and development spending rose. The company had $384.3 million in cash, cash equivalents, and marketable securities at June 30, 2026, and said a July 2026 public offering raised approximately $632.5 million in gross proceeds, which it expects will fund its listed milestones.
Net loss was $44.1 million, or $(0.14) per share, for the quarter ended June 30, 2026, versus $33.9 million, or $(0.12) per share, a year earlier.
R&D expenses were $35.9 million, up from $21.2 million, driven mainly by clinical trial and personnel costs.
Cash, cash equivalents, and marketable securities were $384.3 million at June 30, 2026, before the July offering of approximately $632.5 million in gross proceeds.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Erasca, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →